People · Operator
Named in public records as an officer, director or promoter · active 2020–2022 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. | — | Biotechnology | Series C | $201.0M | $3.3B | 2020 |
| Code Biotherapeutics, Inc. | — | Other Health Care | Series B | $47.5M | $465.8M | 2021 |
Joseph Truitt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joseph Truitt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 1 | 18 |
| Bruce Booth | 1 | 12 |
| Edward Mathers | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| Mitchell S. Bloom | 1 | 7 |
| Mitchell Bloom | 1 | 6 |
| Kevin Starr | 1 | 5 |
| Russ Fein | 1 | 4 |
| THOMAS HUGHES | 1 | 4 |
| Dmitry Kuzmin | 1 | 3 |
| Frank E. Thomas | 1 | 3 |
| Lou Tartaglia | 1 | 3 |
| Victor Stone | 1 | 2 |
| Robert Lin | 1 | 2 |
| Frances Heller | 1 | 2 |
| Bruce S. Booth | 1 | 2 |
| Lou S. Tartaglia | 1 | 1 |
| Dr. Liam S. Ratcliffe | 1 | 1 |
| Carole Ben Maimon, MD | 1 | 1 |
| Ari S. Goldberg | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.